```
     FILE 'HCAOLD' ENTERED AT 10:07:38 ON 16 SEP 2002
L58            0 S L51 OR L57

     FILE 'HCAPLUS' ENTERED AT 10:07:44 ON 16 SEP 2002
L59           10 S L51 OR L57
L60            4 S L59 AND L4-L21
L61            9 S L59 AND (PD<=19991022 OR PRD<=19991022 OR AD<=19991022)
L62            3 S L60 AND L61
L63            1 S L60 NOT L62
L64           10 S L60-L63

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:50:26 ON 16 SEP 2002
L65            9 S L51 OR L57

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 10:50:48 ON 16 SEP 2002
L66           18 DUP REM L64 L65 (1 DUPLICATE REMOVED)

=> fil reg
FILE 'REGISTRY' ENTERED AT 10:51:13 ON 16 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   15 SEP 2002  HIGHEST RN 451445-11-7
DICTIONARY FILE UPDATES:  15 SEP 2002  HIGHEST RN 451445-11-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l32
L1             STR
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov











VAR G1=OH/30/31/35/44
NODE ATTRIBUTES:
NSPEC IS RC AT 12
CONNECT IS M1 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 17 5 39
NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE
L3 3613 SEA FILE=REGISTRY CSS FUL L1
L29 STR



VAR G1=OH/30/31/35/44
REP G2=(0-5) CH2
VAR G3=46/48/53
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 47
CONNECT IS M1 RC AT 49
CONNECT IS M1 RC AT 54
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 39 7 17
NUMBER OF NODES IS 50

STEREO ATTRIBUTES: NONE
L32 323 SEA FILE=REGISTRY SUB=L3 CSS FUL L29

100.0% PROCESSED 3613 ITERATIONS 323 ANSWERS
SEARCH TIME: 00.00.08

=> d his

(FILE 'HOME' ENTERED AT 09:16:06 ON 16 SEP 2002)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 09:16:27 ON 16 SEP 2002
L1 STR
L2 50 S L1 CSS
L3 3613 S L1 CSS FUL
SAV L3 QAZI035/A

FILE 'HCAPLUS' ENTERED AT 09:22:03 ON 16 SEP 2002
E TAKENOUCHI K/AU

```
L4            36 S E3,E14
                 E GAO Q/AU
L5            77 S E3,E10
                 E GAO QING/AU
L6            81 S E3,E17
L7            15 S E61
                 E MANABE K/AU
L8            39 S E3
                 E MANABE KEN/AU
L9           102 S E6
                 E SOGAWA R/AU
L10            4 S E4
                 E TAKANO Y/AU
L11          228 S E3,E4,E11
L12           34 S E14
                 E ISHIZUKA S/AU
L13          149 S E3,E11
                 E TEIJIN/PA,CS
L14        18629 S E1-E4
                 E WO99-JP4826/AP,PRN
                 E WO99-JP5826/AP,PRN
L15            1 S E3,E4
                 E JP98-365209/AP,PRN
L16            1 S E4
L17            1 S E2
L18            1 S E1
                 E JP98-362827/AP,PRN
L19            1 S E4
                 E JP98-302321/AP,RPN
                 E JP98-302321/AP,PRN
L20            1 S E4
L21            1 S L4-L14 AND L15-L20
                 SEL RN
                 SEL RN

     FILE 'REGISTRY' ENTERED AT 09:26:09 ON 16 SEP 2002
L22          182 S E1-E182
L23           70 S L22 AND L3
L24          112 S L22 NOT L23
L25           58 S L23 AND NR>=4
L26           12 S L23 NOT L25
L27              STR L1
L28           22 S L27 SAM SUB=L3
L29              STR L27
L30           14 S L29 CSS SAM SUB=L3
L31            8 S L28 NOT L30
L32          323 S L29 CSS FUL SUB=L3
                 SAV L32 QAZI035A/A
L33           57 S L23 AND L32
L34            1 S L25 NOT L33
L35           35 S L32 AND S/ELS
L36          288 S L32 NOT L35
L37           65 S L36 AND N>=2
L38          223 S L36 NOT L37
L39          166 S L38 NOT L33,L34
L40            7 S L39 AND N/ELS
L41          159 S L39 NOT L40
L42           11 S L41 AND C3/ES
L43          148 S L41 NOT L42
L44          138 S L43 NOT 46.150.18/RID
L45          123 S L44 NOT OC2/ES
L46           50 S L45 AND (OC3 OR OC4 OR OC5 OR OCOC2 OR OCOC3)/ES
L47           73 S L45 NOT L46
```

```
L48          71 S L47 NOT O2C4/ES
L49           9 S L48 AND SI/ELS
L50           3 S L49 AND (C48H86O4SI3 OR C47H88O3SI3 OR C37H66O3SI3)
L51          68 S L48 NOT L50
                SAV L51 QAZI035B/A
L52          58 S L33,L34
L53          15 S L52 AND (OC4 OR OC5)/ES
L54          43 S L52 NOT L53
L55          38 S L54 NOT ?SPIRO?/CNS
L56           3 S L55 AND (NC5/ES OR C41H70O5SI2 OR C42H74O5SI2)
L57          35 S L55 NOT L56
                SAV L57 QAZI035C/A

     FILE 'HCAOLD' ENTERED AT 10:07:38 ON 16 SEP 2002
L58           0 S L51 OR L57

     FILE 'HCAPLUS' ENTERED AT 10:07:44 ON 16 SEP 2002
L59          10 S L51 OR L57
L60           4 S L59 AND L4-L21
L61           9 S L59 AND (PD<=19991022 OR PRD<=19991022 OR AD<=19991022)
L62           3 S L60 AND L61
L63           1 S L60 NOT L62
L64          10 S L60-L63

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:50:26 ON 16 SEP 2002
L65           9 S L51 OR L57

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 10:50:48 ON 16 SEP 2002
L66          18 DUP REM L64 L65 (1 DUPLICATE REMOVED)

     FILE 'REGISTRY' ENTERED AT 10:51:13 ON 16 SEP 2002

=> fil hcaplus uspatall
FILE 'HCAPLUS' ENTERED AT 10:51:36 ON 16 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:51:36 ON 16 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:51:36 ON 16 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l66 bib abs hitrn fhitstr retable tot

L66  ANSWER 1 OF 18  HCAPLUS  COPYRIGHT 2002 ACS       DUPLICATE 1
AN   1990:21201  HCAPLUS
DN   112:21201
TI   Preparation of cyclopentano vitamin D analogs for regulating calcium
     transport and bone resorption and for inducing cell differentiation
     (antineoplastics)
IN   DeLuca, Hector F.; Schnoes, Heinrich K.; Perlman, Kato L.; Kutner, Andrzej
PA   Wisconsin Alumni Research Foundation, USA
SO   U.S., 7 pp.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   US 4851401         A    19890725      US 1988-219101   19880714 <--
     WO 9000541         A1   19900125      WO 1989-US1634   19890418 <--
```

W: AU, CH, DE, DK, GB, HU, JP, KR, NL, SU
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

AU 8934385	A1	19900205	AU 1989-34385	19890418	<--
AU 612029	B2	19910627			
EP 407461	A1	19910116	EP 1989-905008	19890418	<--
EP 407461	B1	19930331			

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

JP 03501259	T2	19910322	JP 1989-504822	19890418	<--
AT 87618	E	19930415	AT 1989-905008	19890418	<--
GB 2220660	A1	19900117	GB 1989-9571	19890426	<--
FR 2634200	A1	19900119	FR 1989-5754	19890428	<--
PRAI US 1988-219101		19880714	<--		
EP 1989-905008		19890418	<--		
WO 1989-US1634		19890418	<--		

OS MARPAT 112:21201

GI



I

AB The title compds. [I; R1, R2, R3 = H, protecting group; X = H, PhSO2; Y = H, (protected) OH, or XY = bond], useful for regulating Ca transport in the intestine and Ca resorption from bone, and for treating neoplastic diseases, are prepd. I (R1 = R2 = R3 = X = Y = H) (II) was prepd. via an intermediary Ph sulfone deriv. (starting materials and intermediates are not specified in the disclosure). II at 125 ng/day produced a >4-fold increase in Ca transport and 2-fold increase in serum Ca in test rats compared with controls; both calcemic and differentiation-inducing activities of II were greater than those of 1,25-dihydroxyvitamin D3.

IT **114694-10-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for regulation of calcium metab. and as antineoplastic)

IT **114694-10-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for regulation of calcium metab. and as antineoplastic)

RN 114694-10-9 HCAPLUS

CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclopentyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2002 ACS
AN 2002:157566 HCAPLUS
DN 136:194682
TI Use of vitamin D derivatives as bone resorption inhibitors
IN **Ishizuka, Seiichi**; **Takenouchi, Kazuya**; Imaizumi, Atsushi; Oue, Yasuhiro; Kurihara, Noriyoshi; Reddy, Sakamuri V.; Roodman, G. David
PA **Teijin** Limited, Japan; University of Texas, Health Science Center
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015894	A2	20020228	WO 2001-US22614	20010822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2002069003	A2	20020308	JP 2000-252177	20000823
	AU 2001084657	A5	20020304	AU 2001-84657	20010822
PRAI	JP 2000-252177	A	20000823		
	JP 2000-2000252177A		20000823		
	WO 2001-US22614	W	20010822		

OS MARPAT 136:194682
GI



I

AB To obtain a bone resorption inhibitor or a treating agent for Paget's disease of bone, there are provided a method of inhibiting bone resorption, comprising administering to a patient a vitamin D antagonist; and a method for treating Paget's disease of bone, comprising administering to a patient a vitamin D antagonist. An example is given showing osteoclast formation suppression activity of I on the osteoclast formation induced by 1.alpha.,25-dihydroxyvitamin D3 from bone marrow cells of normal persons.

IT **401593-62-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D derivs. as bone resorption inhibitors)

IT **401593-62-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D derivs. as bone resorption inhibitors)

RN 401593-62-2 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:290993 HCAPLUS

DN 132:322032
TI Preparation of vitamin D3 derivatives and remedies for inflammatory respiratory diseases containing the same
IN **Takenouchi, Kazuya; Gao, Qingzhi; Manabe, Kenji; Sogawa, Ryo; Takano, Yasuhiro; Ishizuka, Seiichi**
PA **Teijin** Limited, Japan
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	WO 2000024712	A1	20000504		WO 1999-JP5826	19991022	<--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
	AU 9962281	A1	20000515		AU 1999-62281	19991022	<--
	EP 1123921	A1	20010816		EP 1999-949355	19991022	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
	US 2002091109	A1	20020711		US 2002-35219	20020104	<--
	US 2002099039	A1	20020725		US 2002-35211	20020104	<--
	US 2002103173	A1	20020801		US 2002-35217	20020104	<--
PRAI	JP 1998-302321	A	19981023	<--			
	JP 1998-362827	A	19981221	<--			
	JP 1998-365207	A	19981222	<--			
	JP 1998-365208	A	19981222	<--			
	JP 1998-365209	A	19981222	<--			
	WO 1999-JP5826	W	19991022	<--			
	US 2001-830167	A3	20010423				

OS MARPAT 132:322032
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. represented by general formula (I) [wherein R01, R02 being each independently = hydrogen, Me3Si, Et3Si,tert-BuMe2Si, Ac, MeOCH2, or tetrahydro-4H-pyran-2-yl; and Z = a group represented by general formula Q1, Q2, Q3, Q4, (CH2)3C(OH)R51R52; wherein m, n = 0,2; R11, R12 = H, C1-4 alkyl; K = L = M = H; M = H, K and L together form a double bond together with the existing single bond; K = H, L and M together form a double bond together with the existing single bond; CR21R22 = C3-6 cycloalkyl; Q = CFR31, NR31; R21, R22, R23, R31, R45, R46 = H, HO, CO2H, CF3, pentafluoroethyl, C1-4 alkyloxycarbonyl, C2-5 acyloxy, etc.; R32-R35 = H, OH, C1-4 alkyl, C2-5 acyloxy; A, B = H, OH; A and B together form a double bond together with the existing single bond; CXY = CO; one of X and Y = H, the other = OH or C2-5 acyloxy; R41, R42, R43, R44 = H, HO, CF3, pentafluoroethyl, C2-6 acyloxy, C1-4 alkoxy, etc.; D = E = H; D = OH, E = H; D and E or E and R41 together form a double bond together with the existing single bond; R42 = H, HO, CF3, pentafluoroethyl, C2-5 acyloxy, C1-4 alkoxy, etc.; R51 = (un)substituted CONH2, COR55, C(OH)R56R57; R55, R56, R57 = C1-4 alkyl; R52 = Me, Et, CF3, pentafluoroethyl] are prepd.

These compds. are useful as active ingredients of the remedies for inflammatory respiratory diseases, malignant tumor, articular rheumatism, osteoporosis, true diabetes, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypofunction of accessory thyroid, or metabolic disorder of cartilage. Thus, intermediate (II) was coupled with (3S,5R)-3,5-bis(trimethylsilyloxy)-1-octen-7-yne in the presence of Ph3P and tris(dibenzylideneacetone)dipalladium-chloroform adduct in PhMe at 100.degree. for 6 h followed by treatment with lithium tetrafluoroborate and H2SO4 in MeCN for 20 min to give title compd. (III). III, administered at 1-20 .mu.g/kg to air way of golden hamster , inhibited 20-40% neutrophil infiltration in a LPS-induced pneumonia model. A tablet formulation contg. III was prepd.

IT **266343-22-0P 266343-23-1P 266343-75-3P**
266343-85-5P 266343-88-8P 266343-91-3P
266343-93-5P 266344-00-7P 266344-11-0P
266344-17-6P 266344-23-4P 266344-26-7P
266344-35-8P 266344-38-1P 266344-39-2P
266344-40-5P 266344-54-1P 266344-58-5P
266344-60-9P 266344-61-0P 266344-64-3P
266344-65-4P 266344-66-5P 266344-67-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT **266343-73-1P 266343-74-2P 266343-78-6P**
266343-81-1P 266343-82-2P 266344-05-2P
266344-08-5P 266344-14-3P 266344-20-1P
266344-29-0P 266344-32-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT **266343-22-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-22-0 HCAPLUS

CN 2-Pyrrolidinone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-3-methylene-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Chugai Pharmaceutical C	1995			JP 07173133 A	HCAPLUS
Teijin Limited				JP 06329696 A	HCAPLUS
Teijin Limited				US 5604257 A	HCAPLUS
Teijin Limited				EP 970948 A1	HCAPLUS
Teijin Limited	1994			EP 619305 A1	HCAPLUS
Teijin Limited	1998			WO 9858909 A1	HCAPLUS
Teikoku Hormone Mfg Co	1999			JP 1149747 A	

L66 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:27811 HCAPLUS
DN 130:81699
TI Preparation of vitamin D3 derivatives as remedies for inflammatory respiratory diseases and other disorders
IN Tanaka, Hiroko; **Gao, Qingzhi**; **Manabe, Kenji**; Furuya, Minoru; Tabe, Masayasu; **Ishizuka, Seiichi**; Chokki, Manabu; Mitsuhashi, Hiroaki; Kishimoto, Tadashi; Hazato, Atsuo; Sakuma, Yasuji
PA **Teijin** Limited, Japan
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9858909	A1	19981230	WO 1998-JP2813	19980624 <--
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9879328	A1	19990104	AU 1998-79328	19980624 <--
	AU 743399	B2	20020124		
	EP 970948	A1	20000112	EP 1998-929661	19980624 <--
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	US 6028208	A	20000222	US 1999-242665	19990222 <--
PRAI	JP 1997-168803	A	19970625 <--		
	WO 1998-JP2813	W	19980624 <--		

OS MARPAT 130:81699
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Vitamin D3 derivs. [I; R1, R2 = H, trialkylsilyl, etc.; Z = Q, Q1, Q2; R3, R4 = H, OH, etc.; R5-R8 = H, OH, alkyl, acyloxy; R9 = H, OH, alkyl, alkylthio; R10 = H, alkyl, alkoxy; A, B = H, OH, etc.; X, Y = carbonyl oxygen, or one of X and Y = H while another = OH, etc.; X1 = (CH2)n; X2 = (CH2)m; n, m = 0-2; X3 = (CR7R8)m], useful for treatment of inflammatory respiratory diseases, malignant tumors, articular rheumatism, osteoporosis, diabetes mellitus, hypertension, baldness, acne, psoriasis, and dermatitis, are prepd. Thus, II [R11 = CHO] was reacted with 2-ethyl-2-hydroxy-2-cyclopentanone in ethanol contg. KOH to give a mixt. of all 4 possible stereoisomers of the final product [II; R11 = Q3]. One of these stereoisomers showed >40% inhibitor of neutrocyte infiltration in induced pneumonia in hamsters. Pharmaceutical compns. contg. I are described.

IT **218437-01-5P 218437-02-6P 218437-03-7P**
218437-04-8P 218437-05-9P 218437-06-0P
218437-07-1P 218437-08-2P 218437-09-3P
218437-10-6P 218437-11-7P 218437-13-9P
218437-15-1P 218437-17-3P 218437-19-5P
218437-21-9P 218437-23-1P 218437-24-2P
218437-25-3P 218437-30-0P 218437-31-1P
218437-32-2P 218437-33-3P 218437-34-4P
218437-35-5P 218437-36-6P 218437-37-7P
218437-38-8P 218437-39-9P 218437-40-2P
218437-41-3P 218437-42-4P 218437-43-5P
218437-44-6P 218437-45-7P 218437-46-8P
218437-47-9P 218437-48-0P 218437-49-1P
218437-50-4P 218437-51-5P 218437-52-6P
218437-53-7P 218437-54-8P 218437-55-9P
218437-56-0P 218437-57-1P 218437-58-2P
218437-59-3P 218437-60-6P 218437-61-7P
218437-62-8P 218437-63-9P 218437-64-0P
218437-65-1P 218437-66-2P 218437-67-3P
218598-74-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

IT **218437-81-1P 218437-86-6P 218437-95-7P**
218437-96-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

IT **218437-01-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

RN 218437-01-5 HCAPLUS

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-ethyl-2-hydroxy-, (2R,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry, as shown.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Leo Pharmaceutical Prod				EP 412110 A1	HCAPLUS
Leo Pharmaceutical Prod				US 5206229 A	HCAPLUS
Leo Pharmaceutical Prod				WO 8910351 A1	HCAPLUS
Leo Pharmaceutical Prod	1991			JP 03504377 A	
Teijin Ltd				US 5719297 A	HCAPLUS
Teijin Ltd				EP 712843 A1	HCAPLUS
Teijin Ltd				WO 9533716 A1	HCAPLUS
Teijin Ltd	1996			JP 853411 A	

L66 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:102562 HCAPLUS
DN 124:146588
TI Preparation of vitamin D3 derivatives
IN Tabe, Masayasu; Hazato, Atsuo; **Manabe, Kenji; Gao, Qingzhi**; Tanaka, Hiroko
PA **Teijin** Ltd., Japan
SO PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9533716	A1	19951214	WO 1995-JP1145	19950607	<--
	W: CA, US					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	JP 08053411	A2	19960227	JP 1995-137821	19950605	<--
	CA 2168728	AA	19951214	CA 1995-2168728	19950607	<--
	EP 712843	A1	19960522	EP 1995-921131	19950607	<--
	EP 712843	B1	19991117			
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE					
	EP 854138	A2	19980722	EP 1998-101653	19950607	<--
	EP 854138	A3	19980923			
	EP 854138	B1	20010523			
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE					
	EP 854139	A2	19980722	EP 1998-101654	19950607	<--
	EP 854139	A3	19980923			
	EP 854139	B1	20010905			
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE					
	AT 186721	E	19991215	AT 1995-921131	19950607	<--
	ES 2138212	T3	20000101	ES 1995-921131	19950607	<--

	AT 205190	E	20010915	AT 1998-101654	19950607 <--
	JP 08143541	A2	19960604	JP 1995-144474	19950612 <--
	JP 08134052	A2	19960528	JP 1995-147168	19950614 <--
	US 5719297	A	19980217	US 1996-591547	19960206 <--
	US 5986112	A	19991116	US 1997-971201	19971114 <--
	US 6177586	B1	20010123	US 1999-327489	19990608 <--
PRAI	JP 1994-125144	A	19940607 <--		
	JP 1994-220185	A	19940914 <--		
	JP 1994-223229	A	19940919 <--		
	EP 1995-921131	A3	19950607 <--		
	WO 1995-JP1145	W	19950607 <--		
	US 1996-591547	A3	19960206 <--		
	US 1997-971201	A3	19971114 <--		
OS	MARPAT 124:146588				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R = H, C1-7 hydrocarbylsilyl, C2-8 acyl, acetal residue; A = hydroxymethylcyclopentenyl, methyloxotetrahydro-2-furyl, (un)substituted 3-carboxy-3-hydroxybutyl] are prepd. Thus, II (prepn. given) was reacted with III in CHCl3 contg. tris(dibenzylideneacetone)dipa lladium followed by deprotection to give the title compd. I [R = H, A = (2S,4S)-4-methyl-5-oxotetrahydro-2-furyl]. This bound with the 1.alpha.,25-dihydroxyvitamin D3 receptor at a mol ratio of 104:1 compared with 1:1 for 1.alpha.,25-dihydroxyvitamin D3.

IT **173388-33-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of vitamin D3 derivs.)

IT **173388-33-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of vitamin D3 derivs.)

RN 173388-33-5 HCAPLUS

CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2002 ACS
AN 1993:525211 HCAPLUS
DN 119:125211
TI Treatment of asthma with vitamin D3 derivatives
IN Godtfredsen, Wagn Ole
PA Leo Pharamceutical Products Ltd. A/S, Den.
SO Brit. UK Pat. Appl., 17 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2260904	A1	19930505	GB 1992-26958	19921224 <--
PRAI GB 1992-3535		19920219 <--		

AB 1,25-Dihydroxyvitamin D3 derivs. are effective for the treatment of asthma. The medicaments may be dispensed in a spray can, nebulizer, or atomizer. A nebulizer soln. contg. MC 903 2 mg/1000 mL was formulated.
IT **128312-74-3**
RL: BIOL (Biological study)
(asthma treatment with)
IT **128312-74-3**
RL: BIOL (Biological study)
(asthma treatment with)
RN 128312-74-3 HCAPLUS
CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2002 ACS
AN 1993:524825 HCAPLUS
DN 119:124825
TI Hair preparations containing vitamin D3 analogs for treatment of alopecia
IN Godtfredsen, Wagn Ole
PA Leo Pharmaceutical Products Ltd. A/S, Den.
SO Brit. UK Pat. Appl., 11 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2260903	A1	19930505	GB 1992-26957	19921224 <--
PRAI GB 1992-1920		19920129 <--		

AB 1,25-Dihydroxyvitamin D3 derivs. are effective for the prevention and

treatment of alopecia. A cream contg. MC 903 10 .mu.g/g was formulated.

IT **128312-74-3**
RL: BIOL (Biological study)
(alopecia treatment with)

IT **128312-74-3**
RL: BIOL (Biological study)
(alopecia treatment with)

RN 128312-74-3 HCAPLUS
CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2002 ACS
AN 1991:464738 HCAPLUS
DN 115:64738
TI Use of vitamin D compounds to inhibit AIDS virus
IN Pauza, Charles David; Deftos, Leonard John; Deluca, Hector Floyd
PA Wisconsin Alumni Research Foundation, USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9103246	A1	19910321	WO 1990-US5134	19900910 <--
	W: AU, BR, CA, JP, KR				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	CA 2042369	AA	19910312	CA 1990-2042369	19900910 <--
	AU 9064418	A1	19910408	AU 1990-64418	19900910 <--
	EP 443021	A1	19910828	EP 1990-914580	19900910 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04505332	T2	19920917	JP 1990-513750	19900910 <--
	ZA 9007228	A	19910731	ZA 1990-7228	19900911 <--
PRAI	US 1989-405857		19890911 <--		
	US 1990-579341		19900907 <--		
	WO 1990-US5134		19900910 <--		

OS MARPAT 115:64738
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. include I [R4,R5 = H, D, or R4R5 = double or triple bond; R3,R13 = H, (protected) OH, F, D, alkyl; Z = H, (protected) OH; X,Y = H, hydroxy-protecting group; R1 = CF3, CD3, (CH2)qH (q = 1-5); R2 = CF3, CD3, (CH2)pH (p = 1-5), or R1R2 = (CH2)m (M = 2-5); n = 1-5], II (X1,Y1 = H, acyl, alkylsilyl, alkoxyalkyl; U = H, alkyl, hydroxyalkyl, etc.), and III (R2 = H, Me, Et, propyl; X2,Y2 = H, acyl, hydroxy-protecting group). The vitamin D derivs. of the invention inhibit replication of human immunodeficiency virus in human cells and are therefore useful for treatment of AIDS. The compds. are also useful for treating other lentivirus infections and attendant immune and infectious disorders. Prepn. of selected compds. in described. The derivs. of the invention were also studied with regard to cell differentiation activity and Ca mobilization/transport. For example, cyclopentano-1,25-dihydroxy-vitamin D3 (IV) and cyclopentano-1,25-dihydroxy-22E-dehydro-vitamin D3 (V) increased intestinal Ca transport and bone Ca mobilization (serum Ca levels detd.). IV and V were also more active than 1,25-dihydroxy-vitamin D3 in inducing differentiation of HL-60 leukemic cells, making them useful not only as Ca regulating agents but also in the treatment of neoplastic diseases, esp. leukemias. Biol. activity of a variety of other vitamin D derivs. is given.

IT **128312-74-3**
RL: BIOL (Biological study)
(calcium mobilization and leukemic cell line HL-60 differentiation stimulation activity of)

IT **128312-74-3**
RL: BIOL (Biological study)
(calcium mobilization and leukemic cell line HL-60 differentiation stimulation activity of)

RN 128312-74-3 HCAPLUS

CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2002 ACS

AN 1990:478822 HCAPLUS

DN 113:78822

TI Preparation of vitamin D analogs as drugs

IN Calverley, Martin John; Binderup, Lise; Binderup, Ernst Torndal

PA Leo Pharmaceutical Products Ltd., Den.

SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 8910351 A1 19891102 WO 1989-DK79 19890407 <--
W: AU, DK, JP, KR, US
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE
AU 8935443 A1 19891124 AU 1989-35443 19890407 <--
AU 614372 B2 19910829
EP 412110 A1 19910213 EP 1989-905648 19890407 <--
EP 412110 B1 19930707
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
JP 03504377 T2 19910926 JP 1989-504872 19890407 <--
AT 91282 E 19930715 AT 1989-905648 19890407 <--
ZA 8902824 A 19911127 ZA 1989-2824 19890418 <--
DK 9002426 A 19901008 DK 1990-2426 19901008 <--
DK 173457 B1 20001127
US 5206229 A 19930427 US 1990-582944 19901010 <--
PRAI GB 1988-9466 A 19880421 <--
GB 1988-9467 A 19880421 <--
GB 1988-30169 A 19881223 <--
GB 1988-30174 A 19881223 <--
EP 1989-905648 A 19890407 <--
WO 1989-DK79 A 19890407 <--
OS MARPAT 113:78822
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; n = 1-7; R1, R2 = H, alkyl; or CR1R2 may form a carbocyclic ring; R3 = R4 = H; or R3R4 = double bond], useful as immunostimulants, antidiabetics, antihypertensives, antiinflammatories (no data), etc., are prepd. Thus, a 9,10-secosteroid deriv. II was heated with Bu4NF in THF at 60.degree. and the resulting diol III was heated with pyridinium p-toluenesulfonate in EtOH at 50.degree. to give I [R1R2 = (CH2)2, R3 = R4 = H, n = 1]. A dermatol. cream and an oral capsule contg. I as the active ingredient were formulated.

IT **128312-74-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as drug)

IT **128312-98-1P 128332-75-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for vitamin D analogs)

IT **128312-74-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as drug)

RN 128312-74-3 HCAPLUS

CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2002 ACS
AN 1988:455060 HCAPLUS
DN 109:55060
TI Novel convergent synthesis of side-chain-modified analogs of 1.alpha.,25-dihydroxycholecalciferol and 1.alpha.,25-dihydroxyergocalciferol
AU Kutner, Andrzej; Perlman, Kato L.; Lago, Amparo; Schnoes, Heinrich K.; DeLuca, H. F.; Sicinski, Rafal R.
CS Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI, 53706, USA
SO J. Org. Chem. (**1988**), 53(15), 3450-7
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 109:55060
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A convergent synthesis of vitamin D3 analogs such as I (active in differentiation of human leukemia HL 60 cells with diminished calcemic activity) was developed, via the common intermediate II.
IT **114694-10-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antitumor activity of)
IT **114694-10-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antitumor activity of)
RN 114694-10-9 HCAPLUS
CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclopentyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 11 OF 18 USPATFULL
AN 2002:192102 USPATFULL
TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same
IN Takenouchi, Kazuya, Tokyo, JAPAN
Gao, Qingzhi, Tokyo, JAPAN
Manabe, Kenji, Tokyo, JAPAN
Sogawa, Ryo, Tokyo, JAPAN
Takano, Yasuhiro, Tokyo, JAPAN
Ishizuka, Seiichi, Tokyo, JAPAN
PA TEIJIN LIMITED (non-U.S. corporation)
PI US 2002103173 A1 20020801
AI US 2002-35217 A1 20020104 (10)
RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS APPLICATION
LREP SUGHRUE, MION, ZINN,, MACPEAK & SEAS, PLLC, Suite 800, 2100 Pennsylvania Avenue, N.W., Washington, DC, 20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **266343-22-0P 266343-23-1P 266343-75-3P**
266343-85-5P 266343-88-8P 266343-91-3P
266343-93-5P 266344-00-7P 266344-11-0P
266344-17-6P 266344-23-4P 266344-26-7P

266344-35-8P 266344-38-1P 266344-39-2P
266344-40-5P 266344-54-1P 266344-58-5P
266344-60-9P 266344-61-0P 266344-64-3P
266344-65-4P 266344-66-5P 266344-67-6P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT **266343-73-1P 266343-74-2P 266343-78-6P**
266343-81-1P 266343-82-2P 266344-05-2P
266344-08-5P 266344-14-3P 266344-20-1P
266344-29-0P 266344-32-5P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT **266343-22-0P**
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-22-0 USPATFULL

CN 2-Pyrrolidinone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-3-methylene-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 12 OF 18 USPATFULL

AN 2002:186118 USPATFULL

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN
Gao, Qingzhi, Tokyo, JAPAN
Manabe, Kenji, Tokyo, JAPAN
Sogawa, Ryo, Tokyo, JAPAN
Takano, Yasuhiro, Tokyo, JAPAN
Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)

PI US 2002099039 A1 20020725

AI US 2002-35211 A1 20020104 (10)

RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING

PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222

DT Utility

FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **266343-22-0P 266343-23-1P 266343-75-3P**
266343-85-5P 266343-88-8P 266343-91-3P
266343-93-5P 266344-00-7P 266344-11-0P
266344-17-6P 266344-23-4P 266344-26-7P
266344-35-8P 266344-38-1P 266344-39-2P
266344-40-5P 266344-54-1P 266344-58-5P
266344-60-9P 266344-61-0P 266344-64-3P
266344-65-4P 266344-66-5P 266344-67-6P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)
IT **266343-73-1P 266343-74-2P 266343-78-6P**
266343-81-1P 266343-82-2P 266344-05-2P
266344-08-5P 266344-14-3P 266344-20-1P
266344-29-0P 266344-32-5P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)
IT **266343-22-0P**
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)
RN 266343-22-0 USPATFULL
CN 2-Pyrrolidinone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-3-methylene-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 13 OF 18 USPATFULL
AN 2002:172352 USPATFULL
TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same
IN Takenouchi, Kazuya, Tokyo, JAPAN
Gao, Qingzhi, Tokyo, JAPAN
Manabe, Kenji, Tokyo, JAPAN
Sogawa, Ryo, Tokyo, JAPAN
Takano, Yasuhiro, Tokyo, JAPAN
Ishizuka, Seiichi, Tokyo, JAPAN
PA TEIJIN LIMITED (non-U.S. corporation)
PI US 2002091109 A1 20020711
AI US 2002-35219 A1 20020104 (10)
RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **266343-22-0P 266343-23-1P 266343-75-3P**

266343-85-5P 266343-88-8P 266343-91-3P
266343-93-5P 266344-00-7P 266344-11-0P
266344-17-6P 266344-23-4P 266344-26-7P
266344-35-8P 266344-38-1P 266344-39-2P
266344-40-5P 266344-54-1P 266344-58-5P
266344-60-9P 266344-61-0P 266344-64-3P
266344-65-4P 266344-66-5P 266344-67-6P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT **266343-73-1P 266343-74-2P 266343-78-6P**
266343-81-1P 266343-82-2P 266344-05-2P
266344-08-5P 266344-14-3P 266344-20-1P
266344-29-0P 266344-32-5P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT **266343-22-0P**
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-22-0 USPATFULL

CN 2-Pyrrolidinone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-3-methylene-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 14 OF 18 USPATFULL
AN 2001:11048 USPATFULL
TI Vitamin D3 derivative and production process thereof
IN Tabe, Masayasu, Hino, Japan
Hazato, Atsuo, Hino, Japan
Manabe, Kenji, Hino, Japan
Gao, Qinqzhi, Hino, Japan
Tanaka, Hiroko, Hino, Japan
PA Teijin Limited, Osaka, Japan (non-U.S. corporation)
PI US 6177586 B1 20010123
AI US 1999-327489 19990608 (9)
RLI Division of Ser. No. US 1997-971201, filed on 14 Nov 1997, now patented, Pat. No. US 5986112 Division of Ser. No. US 1996-591547, filed on 6 Feb 1996, now patented, Pat. No. US 5719297
PRAI JP 1994-125144 19940607
JP 1994-220185 19940914
JP 1994-223229 19940919

DT Utility
FS Granted
EXNAM Primary Examiner: Trinh, Ba K.
LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
CLMN Number of Claims: 9
ECL Exemplary Claim: 1,4,7,8
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The starting materials for a production process of a vitamin D.sub.3 derivative are disclosed, e.g., a cyclopentene derivative represented by the formula (1-2): ##STR1##

wherein R.sub.1.sup.1 is a hydrogen atom, tri(C.sub.1 to C.sub.7 hydrocarbon) silyl group, C.sub.2 to C.sub.7 acyl group, group forming an acetal bond together with an oxygen atom of a hydroxyl group, and X.sub.1 is a bromine or iodine atom; and a heptanoic acid derivative represented by the formula (2-4): ##STR2##

wherein X.sub.2 is a bromine atom or iodine atom.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **173388-33-5P**
(prepn. of vitamin D3 derivs.)
IT **173388-33-5P**
(prepn. of vitamin D3 derivs.)
RN 173388-33-5 USPATFULL
CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 15 OF 18 USPATFULL
AN 2000:21702 USPATFULL
TI Vitamin D.sub.3 derivative and treating agent for inflammatory respiratory disease using same
IN Gao, Qingzhi, Hino, Japan
Manabe, Kenji, Hino, Japan
Furuya, Minoru, Hino, Japan
Chokki, Manabu, Hino, Japan
Mitsuhashi, Hiroaki, Hino, Japan
Ishizuka, Seiichi, Hino, Japan

Kishimoto, Tadashi, Hino, Japan
Tabe, Masayasu, Iwakuni, Japan
Sakuma, Yasuji, Tokyo, Japan
Hazato, Atsuo, Tokyo, Japan
Tanaka, Hiroko, Palo Alto, CA, United States
PA Teijin Limited, Osaka, Japan (non-U.S. corporation)
PI US 6028208 20000222
WO 9858909 19981230
AI US 1999-242665 19990222 (9)
WO 1998-JP2813 19980624
19990222 PCT 371 date
19990222 PCT 102(e) date
PRAI JP 1997-168803 19970625
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Qazi, Sabiha N.
LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 3247
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are vitamin D.sub.3 derivatives expressed by the following general formula [1] ##STR1## [wherein, R.sub.1 and R.sub.2 are each a hydrogen atom, a trialkylsilyl group, an acetyl group, a methoxymethyl group, or a tetrahydropyranyl group; R.sub.3 and R.sub.4 are each a hydrogen atom, a hydroxyl group, an acyloxy group, an alkyloxy group, an alkylthio group or an alkyl group which is optionally substituted; R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each a hydrogen atom, a hydroxyl group, an alkyl group or an acyloxy group; R.sub.9 is a hydrogen atom, a hydroxyl group, an alkyl group or an alkylthio group; R.sub.10 is a hydrogen atom, an alkyl group or an alkyloxy group; A and B are each a hydrogen atom, a hydroxyl group, or together express a single bond; X and Y express a carbonyl oxygen, or one of them is a hydrogen atom and the other is a hydroxyl group or an acyloxy group; n is an integer of 0 to 2; m is an integer of 0 to 2], and a method for manufacturing the derivatives.

The compounds can be sued as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis and dermatitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **218437-01-5P 218437-02-6P 218437-03-7P**
218437-04-8P 218437-05-9P 218437-06-0P
218437-07-1P 218437-08-2P 218437-09-3P
218437-10-6P 218437-11-7P 218437-13-9P
218437-15-1P 218437-17-3P 218437-19-5P
218437-21-9P 218437-23-1P 218437-24-2P
218437-25-3P 218437-30-0P 218437-31-1P
218437-32-2P 218437-33-3P 218437-34-4P
218437-35-5P 218437-36-6P 218437-37-7P
218437-38-8P 218437-39-9P 218437-40-2P
218437-41-3P 218437-42-4P 218437-43-5P
218437-44-6P 218437-45-7P 218437-46-8P
218437-47-9P 218437-48-0P 218437-49-1P
218437-50-4P 218437-51-5P 218437-52-6P
218437-53-7P 218437-54-8P 218437-55-9P
218437-56-0P 218437-57-1P 218437-58-2P
218437-59-3P 218437-60-6P 218437-61-7P
218437-62-8P 218437-63-9P 218437-64-0P
218437-65-1P 218437-66-2P 218437-67-3P

218598-74-4P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

IT **218437-81-1P 218437-86-6P 218437-95-7P**
218437-96-8P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

IT **218437-01-5P**
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

RN 218437-01-5 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-ethyl-2-hydroxy-, (2R,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 16 OF 18 USPATFULL

AN 1999:146811 USPATFULL

TI Vitamin D.sup.3 derivative and production process thereof

IN Tabe, Masayasu, Hino, Japan
Hazato, Atsuo, Hino, Japan
Manabe, Kenji, Hino, Japan
Gao, Qingzhi, Hino, Japan
Tanaka, Hiroko, Hino, Japan

PA Teijin Limited, Osaka, Japan (non-U.S. corporation)

PI US 5986112 19991116

AI US 1997-971201 19971114 (8)

RLI Division of Ser. No. US 591547

PRAI JP 1994-125144 19940607
JP 1994-220185 19940914
JP 1994-223229 19940919

DT Utility

FS Granted

EXNAM Primary Examiner: Owens, Amelia

LREP Sughrue, Mion, Zinn, Macpeak & Seas,PLLC

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 2852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A vitamin D.sub.3 derivative represented by the following formula: wherein, R is, independently, a hydrogen atom, tri(C.sub.1 to C.sub.7 hydrocarbon)silyl group, C.sub.2 to C.sub.8 acyl group, or group forming

an acetal bond together with an oxygen atom of a hydroxyl group, A is ##STR1## where, R.sup.1 is a methyl group or methylene group, and when R.sup.1 is a methylene group, the bond between the R.sup.1 and the 3-position of the lactone ring is a double bond, R.sup.2 is a hydrogen atom or C.sub.1 to C.sub.3 alkyl group, R.sup.3 is a hydrogen atom, or R.sup.2 and R.sup.3 together indicate a substitutable single methylene group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **173388-33-5P**
(prepn. of vitamin D3 derivs.)
IT **173388-33-5P**
(prepn. of vitamin D3 derivs.)
RN 173388-33-5 USPATFULL
CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 17 OF 18 USPATFULL
AN 1998:17456 USPATFULL
TI Vitamin D.sub.3 derivatives and production process thereof
IN Tabe, Masayasu, Hino, Japan
Hazato, Atsuo, Hino, Japan
Manabe, Kenji, Hino, Japan
Gao, Qingzhi, Hino, Japan
Tanaka, Hiroko, Hino, Japan
PA Teijin Limited, Osaka, Japan (non-U.S. corporation)
PI US 5719297 19980217
WO 9533716 19951214
AI US 1996-591547 19960206 (8)
WO 1995-JP1145 19950607
19960206 PCT 371 date
19960206 PCT 102(e) date
PRAI JP 1994-125144 19940607
JP 1994-220185 19940914
JP 1994-223229 19940919
DT Utility
FS Granted
EXNAM Primary Examiner: Owens, Amelia Averill
LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
CLMN Number of Claims: 15

ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2931
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A vitamin D.sub.3 derivative represented by the following formula: ##STR1## wherein, R is, independently, a hydrogen atom, tri(C.sub.1 to C.sub.7 hydrocarbon)silyl group, C.sub.2 to C.sub.8 acyl group, or group forming an acetal bond together with an oxygen atom of a hydroxyl group, A is ##STR2## where, R.sup.1 is a methyl group or methylene group, and when R.sup.1 is a methylene group, the bond between the R.sup.1 and the 3-position of the lactone ring is a double bond, R.sup.2 is a hydrogen atom or C.sub.1 to C.sub.3 alkyl group, R.sup.3 is a hydrogen atom, or R.sup.2 and R.sup.3 together indicate a substitutable single methylene group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **173388-33-5P**
(prepn. of vitamin D3 derivs.)
IT **173388-33-5P**
(prepn. of vitamin D3 derivs.)
RN 173388-33-5 USPATFULL
CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 18 OF 18 USPATFULL
AN 93:33482 USPATFULL
TI Vitamin D analogues
IN Calverley, Martin J., Herlev, Denmark
Binderup, Lise, T.ang.strup, Denmark
Binderup, Ernst T., T.ang.strup, Denmark
PA Leo Pharmaceutical Products LTD, Ballerup, Denmark (non-U.S. corporation)
PI US 5206229 19930427
WO 8910351 19891102
AI US 1990-582944 19901010 (7)
WO 1989-DK79 19890407
19901010 PCT 371 date
19901010 PCT 102(e) date
PRAI GB 1988-9466 19880421
GB 1988-9467 19880421

GB 1988-30169 19881223
GB 1988-30174 19881223
DT Utility
FS Granted
EXNAM Primary Examiner: Lone, Werren B.
LREP Cushman, Darby & Cushman
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1614
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **128312-74-3P**
(prepn. of, as drug)
IT **128312-98-1P 128332-75-2P**
(prepn. of, as intermediate for vitamin D analogs)
IT **128312-74-3P**
(prepn. of, as drug)
RN 128312-74-3 USPATFULL
CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



=> fil reg
FILE 'REGISTRY' ENTERED AT 10:52:02 ON 16 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 15 SEP 2002 HIGHEST RN 451445-11-7
DICTIONARY FILE UPDATES: 15 SEP 2002 HIGHEST RN 451445-11-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s l51 or l57

L67 103 L51 OR L57

=> d reg tot

1	RN	401593-62-2	REGISTRY
2	RN	**266344-67-6**	REGISTRY
3	RN	**266344-66-5**	REGISTRY
4	RN	**266344-65-4**	REGISTRY
5	RN	**266344-64-3**	REGISTRY
6	RN	**266344-61-0**	REGISTRY
7	RN	**266344-60-9**	REGISTRY
8	RN	**266344-58-5**	REGISTRY
9	RN	**266344-54-1**	REGISTRY
10	RN	**266344-40-5**	REGISTRY
11	RN	**266344-39-2**	REGISTRY
12	RN	**266344-38-1**	REGISTRY
13	RN	**266344-35-8**	REGISTRY
14	RN	**266344-32-5**	REGISTRY
15	RN	**266344-29-0**	REGISTRY
16	RN	**266344-26-7**	REGISTRY
17	RN	**266344-23-4**	REGISTRY
18	RN	**266344-20-1**	REGISTRY
19	RN	**266344-17-6**	REGISTRY
20	RN	**266344-14-3**	REGISTRY
21	RN	**266344-11-0**	REGISTRY
22	RN	**266344-08-5**	REGISTRY
23	RN	**266344-05-2**	REGISTRY
24	RN	**266344-00-7**	REGISTRY
25	RN	**266343-93-5**	REGISTRY
26	RN	**266343-91-3**	REGISTRY
27	RN	**266343-88-8**	REGISTRY
28	RN	**266343-85-5**	REGISTRY
29	RN	**266343-82-2**	REGISTRY
30	RN	**266343-81-1**	REGISTRY
31	RN	**266343-78-6**	REGISTRY
32	RN	**266343-75-3**	REGISTRY
33	RN	**266343-74-2**	REGISTRY
34	RN	**266343-73-1**	REGISTRY
35	RN	**266343-23-1**	REGISTRY
36	RN	**266343-22-0**	REGISTRY
37	RN	218598-74-4	REGISTRY
38	RN	218437-96-8	REGISTRY
39	RN	218437-95-7	REGISTRY
40	RN	218437-86-6	REGISTRY
41	RN	218437-81-1	REGISTRY
42	RN	218437-67-3	REGISTRY
43	RN	218437-66-2	REGISTRY
44	RN	218437-65-1	REGISTRY
45	RN	218437-64-0	REGISTRY
46	RN	218437-63-9	REGISTRY
47	RN	218437-62-8	REGISTRY
48	RN	218437-61-7	REGISTRY
49	RN	218437-60-6	REGISTRY
50	RN	218437-59-3	REGISTRY
51	RN	218437-58-2	REGISTRY
52	RN	218437-57-1	REGISTRY
53	RN	218437-56-0	REGISTRY
54	RN	218437-55-9	REGISTRY
55	RN	218437-54-8	REGISTRY
56	RN	218437-53-7	REGISTRY
57	RN	218437-52-6	REGISTRY
58	RN	218437-51-5	REGISTRY
59	RN	218437-50-4	REGISTRY
60	RN	218437-49-1	REGISTRY

61	RN	218437-48-0	REGISTRY
62	RN	218437-47-9	REGISTRY
63	RN	218437-46-8	REGISTRY
64	RN	218437-45-7	REGISTRY
65	RN	218437-44-6	REGISTRY
66	RN	218437-43-5	REGISTRY
67	RN	218437-42-4	REGISTRY
68	RN	218437-41-3	REGISTRY
69	RN	218437-40-2	REGISTRY
70	RN	218437-39-9	REGISTRY
71	RN	218437-38-8	REGISTRY
72	RN	218437-37-7	REGISTRY
73	RN	218437-36-6	REGISTRY
74	RN	218437-35-5	REGISTRY
75	RN	218437-34-4	REGISTRY
76	RN	218437-33-3	REGISTRY
77	RN	218437-32-2	REGISTRY
78	RN	218437-31-1	REGISTRY
79	RN	218437-30-0	REGISTRY
80	RN	218437-25-3	REGISTRY
81	RN	218437-24-2	REGISTRY
82	RN	218437-23-1	REGISTRY
83	RN	218437-21-9	REGISTRY
84	RN	218437-19-5	REGISTRY
85	RN	218437-17-3	REGISTRY
86	RN	218437-15-1	REGISTRY
87	RN	218437-13-9	REGISTRY
88	RN	218437-11-7	REGISTRY
89	RN	218437-10-6	REGISTRY
90	RN	218437-09-3	REGISTRY
91	RN	218437-08-2	REGISTRY
92	RN	218437-07-1	REGISTRY
93	RN	218437-06-0	REGISTRY
94	RN	218437-05-9	REGISTRY
95	RN	218437-04-8	REGISTRY
96	RN	218437-03-7	REGISTRY
97	RN	218437-02-6	REGISTRY
98	RN	218437-01-5	REGISTRY
99	RN	173388-33-5	REGISTRY
100	RN	128332-75-2	REGISTRY
101	RN	128312-98-1	REGISTRY
102	RN	128312-74-3	REGISTRY
103	RN	114694-10-9	REGISTRY

=> d ide can 1 10 20 30 37 38 45 50 60 70 80 90 99-103

L67 ANSWER 1 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 401593-62-2 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.
Double bond geometry as shown.

Sample compounds from hits



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:194682

L67 ANSWER 10 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN **266344-40-5** REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:322032

L67 ANSWER 20 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN **266344-14-3** REGISTRY
CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C38 H67 N O5 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:322032

L67 ANSWER 30 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN **266343-81-1** REGISTRY
CN Silane, [[(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C43 H76 O3 Si3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:322032

L67 ANSWER 37 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218598-74-4 REGISTRY
CN 1,3-Cyclohexanediol, 5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1S)-2-hydroxy-2-(2-hydroxy-3,3-dimethylcyclopentyl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H46 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 38 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218437-96-8 REGISTRY
CN Cyclopentanone, 2-(acetyloxy)-5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-methyl-, (5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C42 H70 O5 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 45 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218437-64-0 REGISTRY
CN Cyclohexanone, 2-[3-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]butylidene]-, (2Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H42 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 50 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218437-59-3 REGISTRY
CN 1,3-Cyclohexanediol, 5-[(2E)-[(1R,3aS,7aR)-1-[(1R,2E)-2-[(2S,3R)-2,3-dihydroxy-3-methylcyclopentylidene]-1-methylethyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H42 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 60 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218437-49-1 REGISTRY
CN Cyclohexanone, 6-[(1.alpha.,3.beta.,5Z,7E)-1,3-dihydroxy-9,10-secochola-5,7,10(19)-trien-24-ylidene]-2-hydroxy-2-methyl-, (2R,6E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H46 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 70 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218437-39-9 REGISTRY
CN Cycloheptanone, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (2E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H42 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 80 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218437-25-3 REGISTRY
CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-propyl-, (2S,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H44 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 90 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218437-09-3 REGISTRY
CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 99 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 173388-33-5 REGISTRY
CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H42 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:146588

L67 ANSWER 100 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 128332-75-2 REGISTRY
CN Cyclohexanol, 1-[(1.alpha.,3.beta.,5Z,7E)-1,3-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9,10-secochola-5,7,10(19)-trien-24-yl]-(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,10-Secocholane, cyclohexanol deriv.
MF C42 H76 O3 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:78822

L67 ANSWER 101 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 128312-98-1 REGISTRY
CN Cyclohexanol, 1-[(1.alpha.,3.beta.,5E,7E)-1,3-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9,10-secochola-5,7,10(19)-trien-24-yl]-(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,10-Secocholane, cyclohexanol deriv.
MF C42 H76 O3 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:78822

L67 ANSWER 102 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 128312-74-3 REGISTRY
CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)
MF C30 H48 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 119:125211

REFERENCE 2: 119:124825

REFERENCE 3: 115:64738

REFERENCE 4: 113:78822

L67 ANSWER 103 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 114694-10-9 REGISTRY
CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclopentyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)
MF C29 H46 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:21201

REFERENCE 2: 109:55060